SCHEMBL23934279

SCHEMBL23934279

CC(=O)Nc1cc(NC(C)=O)c2c(c1)C(=O)N(C)C2=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.43
MAPT P10636 2/20 0.43
ALDH1A1 P00352 9/20 0.42
KDM4E B2RXH2 7/20 0.42
LMNA P02545 1/20 0.41
POLB P06746 2/20 0.40
GAA P10253 1/20 0.40
HSD17B10 Q99714 4/20 0.40
ERCC1 P07992 2/20 0.40
FEN1 P39748 2/20 0.40
ERCC4 Q92889 2/20 0.40
DNASE1 P24855 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 1/20 0.40
MAOA P21397 1/20 0.40
RAB9A P51151 1/20 0.40
TP53 P04637 1/20 0.39
CA12 O43570 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23963036 0.83 HPGD (0.43) HPGDMAPTALDH1A1KDM4EPOLB
SCHEMBL9437183 0.78 RXFP1 (0.44) HPGDMAPTALDH1A1KDM4ELMNA
SCHEMBL23934281 0.77 MEN1 (0.53) HPGDMAPTALDH1A1KDM4ELMNA
SCHEMBL18826569 0.76 HPGD (0.71) HPGDMAPTALDH1A1KDM4EPOLB
SCHEMBL23934204 0.73 KDM4E (0.54) HPGDMAPTALDH1A1KDM4ELMNA
SCHEMBL23934214 0.73 LMNA (0.53) MAPTALDH1A1LMNAPOLBSMN1; SMN2
SCHEMBL23934278 0.72 MAPT (0.54) MAPTALDH1A1KDM4ELMNAPOLB
SCHEMBL8765742 0.68 LMNA (0.61) HPGDMAPTALDH1A1LMNAPOLB
SCHEMBL8765733 0.68 LMNA (0.56) HPGDMAPTALDH1A1KDM4ELMNA
SCHEMBL28485570 0.68 LMNA (0.56) HPGDMAPTALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS XAVIER UNIVERSITY OF LOUISIANA 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS RPS6KA6, RPS6KA1, RPS6KA3 HPGD 4094/4885MAPT 1837/4885ALDH1A1 4396/4885
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics RPS6KA6, RPS6KA1, RPS6KA3 HPGD 4094/4885MAPT 1837/4885ALDH1A1 4396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.